Zhiyuan SONG. How to balance the risks and benefits of left atrial appendage closure?[J]. Journal of Third Military Medical University, 2019, 41(19): 1851-1854.
DOI:
Zhiyuan SONG. How to balance the risks and benefits of left atrial appendage closure?[J]. Journal of Third Military Medical University, 2019, 41(19): 1851-1854. DOI: 10.16016/j.1000-5404.201908074.
How to balance the risks and benefits of left atrial appendage closure?
Left atrial appendage closure (LAAC) is a new technique to prevent ischemic stroke in patients with non-valvular atrial fibrillation (NVAF)
and recommended by international and domestic guidelines due to its confirmed efficacy and safety in clinical practice. However
its benefits have always been coexisting with some risks. So
how to balance the risks and benefits is one of the important issues concerned by clinical professionals. Based on randomized clinical trials
this manuscript systematically introduces the evidence-based medicine of LAAC in preventing ischemic stroke with NVAF patients
elucidates incidence of complications and major complications of LAAC
then puts forward specific measurement of reducing risks and increasing benefits in clinical practice.
关键词
Keywords
references
KIRCHHOF P, BENUSSI S, KOTECHA D, et al . 2016 ESC Guidelines for themanagement of atrial fibrillation developed in collaboration with EACTS[J ] . Eur Heart J, 2016, 37(38): 2893-2962. DOI:10.1093/eurheartj/ehw210.
JANUARY C T, WANN L S, CALKINS H, et al . 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons[J ] . Circulation, 2019, 140(2): e125-e151. DOI:10.1161/CIR.0000000000000665.
HUANG C X, ZHANG S, HUANG D J, et al . Atrial fibrillation: current understanding and treatment recommendations-2018[J ] . Chin J Cardiac Arrhyth, 2018, 22(4) : 279-346. DOI: 10.3760/cma.j.issn.1007-6638.2018.04.002.
YAO Q, SONG Z Y, SHU M Q, et al . Clinical applicationof Watchman occluder for left atrial appendage occlusion[J ] . J Third Mil Med Univ, 2014, 36(20): 2129-2132. DOI:10.16016/j.1000-5404.2014.20.002.
REDDY V Y, SIEVERT H, HALPERIN J, et al . Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial[J ] . JAMA, 2014, 312(19): 1988-1998. DOI:10.1001/jama.2014.15192.
HOLMES D R Jr, KAR S, PRICE M J, et al . Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial[J ] . J Am Coll Cardiol, 2014, 64(1): 1-12. DOI:10.1016/j.jacc.2014.04.029.
REDDY V Y, DOSHI S K, KAR S, et al . 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials[J ] . J Am Coll Cardiol, 2017, 70(24): 2964-2975. DOI:10.1016/j.jacc.2017.10.021.
BOERSMA L V, INCE H, KISCHE S, et al . Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial[J ] . Heart Rhythm, 2017, 14(9): 1302-1308. DOI:10.1016/j.hrthm.2017.05.038.
BOERSMA L V, INCE H, KISCHE S, et al . Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology. Final 2-year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage[J ] . Circ Arrhythm Electrophysiol, 2019, 12:e006841. DOI:10.1161/CIRCEP.118.006841.
REDDY V Y, MÖBIUS-WINKLER S, MILLER M A, et al . Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA plavix feasibility study with watchman left atrial appendage closure technology)[J ] . J Am Coll Cardiol, 2013, 61(25): 2551-2556. DOI:10.1016/j.jacc.2013.03.035.
SHARMA D, REDDY V Y, SANDRI M , et al . Left atrial appendage closure in patients with contraindications to oral anticoagulation[J ] . J Am Coll Cardiol, 2016, 67(18): 2190-2192. DOI:10.1016/j.jacc.2016.02.053.
SICK P B, SCHULER G, HAUPTMANN K E, et al . Initial worldwide experience with theWATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation[J ] . J Am Coll Cardiol, 2007, 49(13): 1490-1495. DOI:10.1016/j.jacc.2007.02.035.
PARK J W, BETHENCOURT A, SIEVERT H, et al . Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience[J ] . Catheter Cardiovasc Interv, 2011, 77(5): 700-706. DOI:10.1002/ccd.22764.
REDDY V Y, GIBSON D N, KAR S, et al . Post-approval US experience with left atrial appendage closure for stroke prevention in atrial fibrillation[J ] . J Am Coll Cardiol, 2017, 69(3): 253-261. DOI:10.1016/j.jacc.2016.10.010.
YAO Q, SONG Z Y, GUO Y L, et al . Application of left atrial appendage occlusion in patients with nonvalvular atrial fibrillation : experience of one center[J ] . Chin J Inte rv Cardiol, 2018, 26(10):553-558. DOI: 10.3969/j.issn.1004-8812.2018.10.004.